Seres Therapeutics (MCRB) Cash from Investing Activities (2014 - 2026)
Seres Therapeutics (MCRB) posted Cash from Investing Activities of $181000.0 for Q4 2025, up 2362.5% sequentially from -$8000.0 in Q3 2025, and up 301.11% YoY from $45124.7 in Q4 2024.
Seres Therapeutics (MCRB) Cash from Investing Activities (2014 - 2026) Analysis & Trends
Seres Therapeutics has reported Cash from Investing Activities for 12 years, with the latest figure at $181000.0 in Q4 2025.
- Quarterly Cash from Investing Activities rose 301.11% year-over-year to $181000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$8000.0 (down 100.01% YoY) and the FY2025 annual result came in at -$42000.0, down 100.03% from the prior year.
- Cash from Investing Activities grew to $181000.0 in Q4 2025 per MCRB's latest filing, from -$8000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $141.1 million in Q3 2024 and troughed at -$20.7 million in Q1 2021.
- A 5-year average of $15.0 million and a median of $2.0 million in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2021 and 2024: Cash from Investing Activities tumbled 319.75% in 2021, then surged 7954.37% in 2024.
- Over 5 years, Cash from Investing Activities stood at $13.2 million in 2021, then slumped by 55.06% to $5.9 million in 2022, then slumped by 114.8% to -$877000.0 in 2023, then surged by 89.74% to -$90000.0 in 2024, then jumped by 301.11% to $181000.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $181000.0, -$8000.0, and -$181000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - | 14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14,000.00 |
| Jun 30, 2026 | 14,000.00 |
| Dec 31, 2025 | 181,000.00 |
| Dec 31, 2025 | 181,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Jun 30, 2025 | -181,000.00 |
| Jun 30, 2025 | -181,000.00 |
| Mar 31, 2025 | -34,000.00 |
| Mar 31, 2025 | -34,000.00 |
| Dec 31, 2024 | -90,000.00 |
| Dec 31, 2024 | -90,000.00 |
| Sep 30, 2024 | 141.14 Mn |
| Sep 30, 2024 | 141.14 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | -62,000.00 |
| Mar 31, 2024 | -62,000.00 |
| Dec 31, 2023 | -877,000.00 |
| Dec 31, 2023 | -877,000.00 |